<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02840461</url>
  </required_header>
  <id_info>
    <org_study_id>71591701</org_study_id>
    <nct_id>NCT02840461</nct_id>
  </id_info>
  <brief_title>Clinical Endpoint Study of Ivermectin 1% Cream</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Ivermectin Cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (Ivermectin) Cream 1% (Galderma) in the Treatment of Moderate to Severe Papulopustular Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled, parallel-design, multiple-site clinical study
      to evaluate the therapeutic equivalence and safety of ivermectin cream 1% (Actavis
      Laboratories UT, Inc.) to SoolantraTM (ivermectin) cream 1% (Galderma) in the treatment of
      moderate to severe papulopustular rosacea.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline to Week 12 in the Number of Inflamed (Papules/Pustules) Lesions of Rosacea.</measure>
    <time_frame>Baseline and 12 Weeks</time_frame>
    <description>Bioequivalence of the test to reference was considered to have been demonstrated if the 90% confidence interval for the test to reference ratio for the percent change from baseline to Week 12 in the number of inflamed lesion counts was within [80%, 125%].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Patients With a Clinical Response of &quot;Success&quot;.</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The secondary endpoint was the percentage of patients with a clinical response of &quot;success&quot; using the IGE at Week 12. At Visit 1, the IGE had to be 3 or 4 for the patient to be eligible for inclusion.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">630</enrollment>
  <condition>Moderate to Severe Papulopustular Rosacea</condition>
  <arm_group>
    <arm_group_label>Ivermectin Cream, 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>test product, manufactured by Actavis Laboratories UT, Inc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SoolantraTM (ivermectin) Cream, 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>reference product, manufactured by Galderma Laboratories, L.P.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Vehicle cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, manufactured by Actavis Laboratories UT, Inc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin Cream, 1%</intervention_name>
    <arm_group_label>Ivermectin Cream, 1%</arm_group_label>
    <arm_group_label>SoolantraTM (ivermectin) Cream, 1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo/Vehicle cream</intervention_name>
    <arm_group_label>Placebo/Vehicle cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent that meets all criteria of current FDA regulations.

          2. Healthy male or non-pregnant, non-lactating female greater than or equal to 8 years of
             age with a clinical diagnosis of moderate to severe papulopustular rosacea, defined as
             the presence of:

             A total of 8 to 50 combined papules/pustules on the face, AND At least moderate
             erythema, AND Telangiectasia

          3. Patient has a baseline Investigator's Global Evaluation (IGE) score of 3 (moderate) or
             4 (severe) for rosacea severity (See Appendix A).

          4. Females of child bearing potential must not be pregnant or lactating at Screening (as
             confirmed by a negative urine pregnancy test with a sensitivity of less than 25 mlU/mL
             or equivalent units of human chorionic gonadotropin). Women of childbearing potential
             must agree to the use of a reliable method of contraception (e.g., total abstinence,
             IUD, a double-barrier method [such as condom plus diaphragm with spermicide], oral,
             transdermal, injected or implanted non- or hormonal contraceptive), throughout the
             study. If the female is using a hormonal contraceptive, the same product must be taken
             for 3 months prior to Visit 1 and must agree not to replace with some other hormonal
             contraceptives during the study. A sterile sexual partner is not considered an
             adequate form of birth control.

             All females will be considered to be of childbearing potential unless they: Are
             post-menopausal, defined as women who have been amenorrheic for at least 12
             consecutive months, without other known or suspected primary cause.

             Have been sterilized surgically or who are otherwise proven sterile (i.e., total
             hysterectomy, or bilateral oophorectomy) with surgery at least 4 weeks before
             Screening. Tubal ligation will not be considered a surgically sterile method.

             Female patients of childbearing potential are defined as Women without prior
             hysterectomy of at least 4 weeks, or who have had any evidence of menses in the past
             12 months.

             Females who have been amenorrhea for more than or equal to 12 months, but the
             amenorrhea is possibly due to other causes, including prior chemotherapy,
             anti-estrogens, or ovarian suppression.

          5. Free from any systemic or dermatologic disorder that, in the opinion of the
             Investigator, will interfere with the study results or increase the risk of adverse
             events.

          6. Willing to minimize external factors that might trigger rosacea flare-ups (e.g.,
             extreme temperatures, aggressive astringents, known offending foods such as spicy
             foods and thermally hot foods and drinks, prolonged sun exposure, strong winds,
             alcoholic beverages, and emotional stress) within 24 hours before the Screening visit.

          7. Of any skin type or race, provided the skin pigmentation allows accurate evaluation of
             papulopustular rosacea.

          8. Willingness and capability to cooperate to the extent and degree required by the
             protocol.

        Exclusion Criteria:

          1. Females who are pregnant, lactating or planning to become pregnant during the study
             period.

          2. Patient has mild facial rosacea (less than 8 inflammatory lesions on the face) or very
             severe rosacea (more than 50 inflammatory lesions).

          3. Patient has mild erythema.

          4. Patient has a baseline IGE score of 0, 1 or 2.

          5. Patient has a skin condition on the face that would interfere with the diagnosis or
             assessment of rosacea (e.g., dermatitis, psoriasis, squamous cell carcinoma, eczema,
             acneform eruptions caused by medications, steroid acne, steroid folliculitis,
             bacterial folliculitis).

          6. Patients with excessive facial hair, such as beards, sideburns, moustaches, etc., that
             would interfere with diagnosis or assessment of rosacea.

          7. Patients with tattoos or excessive facial scarring that, in the Investigator's
             opinion, may interfere with the evaluation of the patient's rosacea.

          8. Patients with active facial sunburn, peeling from sunburn, or patients that will be
             exposed to excessive sunlight during the study.

          9. Patient has significant history or current evidence of chronic infectious disease,
             system disorder, organ disorder or other medical condition that in the Investigator's
             opinion would place the study patient at undue risk by participation.

         10. Any patient (male or female) who has started, or changed hormonal therapy within 3
             months of the baseline visit (this includes hormonal contraceptives). Patients who
             have been on stable hormone therapy for at least 3 months and whose therapy is
             considered unlikely to be changed for the duration of the study will be eligible.

         11. History of hypersensitivity or allergy to study drug, or other ingredients of the
             formulation.

         12. Use within 6 months prior to baseline of oral retinoids (e.g., Accutane) or
             therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are
             allowed).

         13. Use for less than 3 months prior to baseline of estrogen- and/or progestin-containing
             oral, injectable, implant, or transdermal contraceptives; use of such therapy must
             remain constant throughout the study.

         14. Use within 1 month prior to baseline of 1) topical retinoids to the face, 2) systemic
             (e.g., oral or injectable) antibiotics known to have an impact on the severity of
             facial rosacea (e.g., containing tetracycline and its derivatives, erythromycin and
             its derivatives, sulfamethoxazole, or trimethoprim), 3) systemic steroids, 4)
             photodynamic therapy (including laser and other light therapies), or 6) cosmetic
             procedures (e.g., superficial chemical peels, exfoliation or microdermabrasion of the
             face).

         15. Use within 2 weeks prior to baseline of 1) topical corticosteroids, 2) topical
             antibiotics, 3) topical anti-inflammatory agents or 4) topical medications for rosacea
             (e.g., metronidazole, azelaic acid, sodium sulfacetamide, ivermectin) 5)
             immunosuppressive drugs, 6) anticoagulant therapy.

         16. Use of any other topical products applied to the target site.

         17. Use of systemic corticosteroids. The use of inhaled corticosteroids up to less than
             1mg per day is acceptable.

         18. Use of antipruritics, including antihistamines, within 24 hours of study visits.

         19. Patients who use make-up must have used the same brands/types for a minimum period of
             14 days before study entry and must agree to not change brand or frequency of use
             throughout the study.

         20. Presence of carcinoid, pheochromocytoma, or other causes of systemic flushing.

         21. Presence of acne conglobata, acne fulminans, secondary acne or severe acne requiring
             systemic treatment.

         22. Ocular rosacea (e.g., conjunctivitis, blepharitis, or keratitis) of sufficient
             severity to require topical or systemic antibiotics.

         23. Receipt of any drug as part of a research study within 30 days before dosing.

         24. Employees of the research center or Investigator.

         25. Patients who are illiterate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigator site 1</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 19, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2016</study_first_posted>
  <results_first_submitted>April 13, 2020</results_first_submitted>
  <results_first_submitted_qc>May 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 2, 2020</results_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ivermectin Cream, 1%</title>
          <description>Test product, manufactured by Actavis Laboratories UT, Inc.
Ivermectin Cream, 1%</description>
        </group>
        <group group_id="P2">
          <title>SoolantraTM (Ivermectin) Cream, 1%</title>
          <description>Reference product, manufactured by Galderma Laboratories, L.P.
Ivermectin Cream, 1%</description>
        </group>
        <group group_id="P3">
          <title>Placebo/Vehicle Cream</title>
          <description>Placebo, manufactured by Actavis Laboratories UT, Inc.
Placebo/Vehicle cream</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="259"/>
                <participants group_id="P2" count="257"/>
                <participants group_id="P3" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="236"/>
                <participants group_id="P2" count="235"/>
                <participants group_id="P3" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Comliance with Dosing Requirements</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Worsening of Symptom &amp; Kit Error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ivermectin Cream, 1%</title>
          <description>Test product, manufactured by Actavis Laboratories UT, Inc.
Ivermectin Cream, 1%</description>
        </group>
        <group group_id="B2">
          <title>SoolantraTM (Ivermectin) Cream, 1%</title>
          <description>Reference product, manufactured by Galderma Laboratories, L.P.
Ivermectin Cream, 1%</description>
        </group>
        <group group_id="B3">
          <title>Placebo/Vehicle Cream</title>
          <description>Placebo, manufactured by Actavis Laboratories UT, Inc.
Placebo/Vehicle cream</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="259"/>
            <count group_id="B2" value="257"/>
            <count group_id="B3" value="114"/>
            <count group_id="B4" value="630"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="15.4"/>
                    <measurement group_id="B2" value="50.3" spread="15.0"/>
                    <measurement group_id="B3" value="51.1" spread="14.1"/>
                    <measurement group_id="B4" value="51.1" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="182"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="449"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="334"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="296"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="253"/>
                    <measurement group_id="B2" value="253"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="620"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline to Week 12 in the Number of Inflamed (Papules/Pustules) Lesions of Rosacea.</title>
        <description>Bioequivalence of the test to reference was considered to have been demonstrated if the 90% confidence interval for the test to reference ratio for the percent change from baseline to Week 12 in the number of inflamed lesion counts was within [80%, 125%].</description>
        <time_frame>Baseline and 12 Weeks</time_frame>
        <population>Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ivermectin Cream, 1%</title>
            <description>Test product, manufactured by Actavis Laboratories UT, Inc.
Ivermectin Cream, 1%</description>
          </group>
          <group group_id="O2">
            <title>SoolantraTM (Ivermectin) Cream, 1%</title>
            <description>Reference product, manufactured by Galderma Laboratories, L.P.
Ivermectin Cream, 1%</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Cream</title>
            <description>Placebo cream (manufactured by Actavis Laboratories UT, Inc.)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in the Number of Inflamed (Papules/Pustules) Lesions of Rosacea.</title>
          <description>Bioequivalence of the test to reference was considered to have been demonstrated if the 90% confidence interval for the test to reference ratio for the percent change from baseline to Week 12 in the number of inflamed lesion counts was within [80%, 125%].</description>
          <population>Modified Intent-to-Treat Population</population>
          <units>percentage of change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-64.87" spread="2.03"/>
                    <measurement group_id="O2" value="-64.87" spread="2.03"/>
                    <measurement group_id="O3" value="-55.04" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Therapeutic equivalence of the Test product to the Reference product based on the primary endpoint was evaluated in the PP population. If the confidence interval is within 80-125% for the primary endpoint, then the Test and Reference treatments are considered therapeutically equivalent.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>103.51</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.95</ci_lower_limit>
            <ci_upper_limit>110.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0027</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-9.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.24</ci_lower_limit>
            <ci_upper_limit>-3.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0028</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-9.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.25</ci_lower_limit>
            <ci_upper_limit>-3.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Patients With a Clinical Response of &quot;Success&quot;.</title>
        <description>The secondary endpoint was the percentage of patients with a clinical response of &quot;success&quot; using the IGE at Week 12. At Visit 1, the IGE had to be 3 or 4 for the patient to be eligible for inclusion.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Modified Intent-To-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ivermectin Cream, 1%</title>
            <description>Test product, manufactured by Actavis Laboratories UT, Inc.
Ivermectin Cream, 1%</description>
          </group>
          <group group_id="O2">
            <title>SoolantraTM (Ivermectin) Cream, 1%</title>
            <description>Reference product, manufactured by Galderma Laboratories, L.P.
Ivermectin Cream, 1%</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Cream</title>
            <description>Placebo Cream: manufactured by Actavis Laboratories UT., Inc.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients With a Clinical Response of &quot;Success&quot;.</title>
          <description>The secondary endpoint was the percentage of patients with a clinical response of &quot;success&quot; using the IGE at Week 12. At Visit 1, the IGE had to be 3 or 4 for the patient to be eligible for inclusion.</description>
          <population>Modified Intent-To-Treat Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% confidence interval (with Yates correction) for the difference between the proportion of patients in the Test and Reference groups considered to be a clinical success was contained within the pre-defined equivalence limits [-20%, +20%], the therapeutic equivalence of the Test to Reference product was considered supported.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>5.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>14.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ivermectin Cream, 1%</title>
          <description>Test product, manufactured by Actavis Laboratories UT, Inc.
Ivermectin Cream, 1%</description>
        </group>
        <group group_id="E2">
          <title>SoolantraTM (Ivermectin) Cream, 1%</title>
          <description>Reference product, manufactured by Galderma Laboratories, L.P.
Ivermectin Cream, 1%</description>
        </group>
        <group group_id="E3">
          <title>Placebo/Vehicle Cream</title>
          <description>Placebo, manufactured by Actavis Laboratories UT, Inc.
Placebo/Vehicle cream</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pnuemonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Sjogren's syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="257"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="257"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director, CE Studies</name_or_title>
      <organization>Teva Pharmaceuticals Inc. USA</organization>
      <phone>1-888-483-8279</phone>
      <email>USMedInfo@tevapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

